Slide 1: A New Global Market Force in Histology and Cytology Cancer Diagnostics
1 OTC BB CYOE A New Global Market Force in Histology and Cytology Cancer Diagnostics
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended, regarding future operating performance, events, trends and plans . All
Slide 3: Transaction Summary
Transaction Summary • Entered into Stock Purchase Agreement (SPA) on January 11, 2013, creating global market force in histology and cytology markets • CytoCore to acquire 100% of the capital stock of MEDITE • Purchase will be funded by the issuance of 1.5 billion restricted shares to the shareholde
Slide 4: MEDITE is…
MEDITE is… …specializing in the manufacturing and marketing of superior molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and related diseases. The Company is emerging as rapidly growing disruptive force in the multi - billion dollar global histo
Slide 5: MEDITE…Consistently Profitable Operations
MEDITE…Consistently Profitable Operations • Founded in 1978 in Germany; focus on engineering laboratory process automation and supply products for histology and cytology…total solution approach! • Recognized histology innovator: - first programable Multistainer - first three piece Embedding Center,
Slide 6: Investment Considerations
Investment Considerations • Large addressable markets with double digit growth rates - 1.6 million new cancer patients annually in the U.S. • Global leader in cytology and histology; focus on molecular marker • Executed new multi - year contracts & product development pipeline positions CytoCore and
Slide 7: Large addressable and growing market
7 Large addressable and growing market
Slide 8: Cancer is defined, diagnosed and classified on the basis of cell and tissue morphology
8 Cancer is defined, diagnosed and classified on the basis of abnormalities in cell (cytology) and tissue (histology) morphology Challenge Biomarkers: • There are no known biomarkers that are unique and definitive for cancer • Biomarkers are good for classification, but poor for screening & diagnosi
Slide 9: Compelling Merger Advantages
MEDITE • Premium I nternational Brand • Proven Business Model • Complete Histology Product Line Coverage • Strong Engineering Capabilities CYTOCORE • Strong Bio Marker Research Capabilities • Cancer Marker • Public Company with Probable NOLs MEDITE AND CYTOCORE • Cytology Cancer Screening • Go to Ma
Slide 10: Advanced Engineered Product Portfolio
Advanced Engineered Product Portfolio 10
Slide 11: Leading Labs into the Future: Histology
Leading Labs into the Future: Histology 11 • Automation - Fastest Stainer - Coverslipper - System, Histology lab - in - one Instrument under development • Flexibility - Tissue Processor TPC TRIO • Speed - COT (stains 1,000 slides/h), USE (decalcify 4 times faster than just acid), Tape (covers 4 time
Slide 12: MEDITE Highly Engineered Histology Products
MEDITE Highly Engineered Histology Products 12
Slide 13: Significant OEM Agreements
• Signed five year agreement to supply MEDITE’s newly developed and patented Stainer - Coverslipper - Combination to an Industry leader • Additional OEM agreements are under negotiation Significant OEM Agreements 13
Slide 14: Leading Labs into the Future: Cytology
Leading Labs into the Future: Cytology 14 • Automation - Development of fully automated slide preparation and imaging system for Liquid Based Cytology • Flexibility - Providing all equipment and consumables for replacing both leading Systems (Becton - Dickinson/Hologic). Also for non - GYN LBC consu
Slide 15: MEDITE: Cytology Product Price Performance Leader
MEDITE: Cytology Product Price Performance Leader 15
Slide 16: CytoCore Solutions
16 Collection Detection Evaluation Slide Preparation • SoftPAP ® • SoftKit • Breast Aspirant Cell Collector • Preservative • Instrument • Morphology stains • Molecular Assays • Workstation • Imager • DMS CytoCore Solutions
Slide 17: CytoCore Breast Aspirant-cell Collector
• Breast cancer is a leading (health) cause of death for women in the U.S.; 50,000 annually • 12% of U.S. Female population develop disease; 200,000 cases • Self - examination only procedure available for women between 20 - 40 years of age • Mammography incurs additional cancer risk and has low sens
Slide 18: CytoCore's Molecular Biomarker Immunoassays
18 Assay Type & Use Time to Preproduction Tests T - 1 Immunoassay: resolution of ASCUS 9 - 12 months A - 1 Immunoassay: resolution of ASCUS 9 - 12 months D - 1 Immunoassay: particularly good for detecting HSIL and CIS 9 - 12 months L1, L2, L3 Immunoassays: predictive tests for progression of dysplas
Slide 19: Novel CytoCore Stains, Markers and Assays
Novel CytoCore Stains, Markers and Assays 19 How CytoCore Assays Work: • Synergistic combinations of selected biomarkers with cell morphology in a single test - Proprietary quantitative “no wash” “instant” morphology stain - Biomarkers are selected to detect cells that are or that have committed to
Slide 20: Significant Barriers to Entry
20 Significant Barriers to Entry • Strong IP portfolio of patents, including industry changing new applications, brands, trademarks • Proprietary equipment manufacturing expertise and biomarker formulation • MEDITE’s brand products are renowned for high quality and reliability - ‘Made in Germany’ ap
Slide 21: 2012 Full Year Financial Performance
2012 Full Y ear F inancial P erformance Cautionary Note : The following summary financial data is based upon historic financial statements provided to us by management of MEDITE . We intend to file a current report on Form 8 - K containing the historic audited financial statements and unaudited inte
Slide 22: Key Milestones
Key Milestones 2013 • Start production of new product TES Valida, TDO Sahara, TFB 35 • Start production of new Cover Tape • Build a strong distribution channel to Chinese market • Create strong U.S. distribution channel for LBC • Finish Version 3 of Stainer - Coverslipper - Combination 2014 • Create
Slide 23: Factors Driving 50% 2014 Growth
Factors Driving 50% 2014 Growth • Generate China sales through newly formed joint venture • Major North America distribution agreement for Histology products with Medline Industries • Major North America distribution agreement for Cytology products • OEM equipment and supply contracts • Breast cance
Slide 24: Experienced Management Team
Experienced Management Team • Michaela Ott – CEO - 20+ years Experience in High Tech and Health Care Industry Sales and Marketing - Shareholder and Officer of FiberTech for 10 years and since 2006 shareholder and Officer of Medite • Michael Ott – President & COO - 14+ years Experience in Operations
Slide 25: Why MEDITE?
Why MEDITE? • Projected CAGR of 50% due to new business momentum through 2016 • Pipeline of proprietary products including high margin stains, molecular biomarkers and consumable products • Significant barriers to entry • Global partners provide a growing base of reliable and stable worldwide custom
Slide 26: A New Global Market Force in Histology and Cytology Cancer Diagnostics
26 OTC BB CYOE A New Global Market Force in Histology and Cytology Cancer Diagnostics